Europe
The two companies joined their consumer health businesses in order to give the parent companies more maneuverability to focus on the pharmaceuticals.
sphingotec launches a CE-marked point-of-care IVD assay for Proenkephalin (penKid(R)), the company’s proprietary biomarker for real-time assessment of kidney function in critical care settings
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation technologies, announces that it has exercised its option to exclusively license a novel Base Editing technology from Rutgers, The State University of New Jersey, for use in therapeutic, diagnostic and service applications.
Xyall BV has been identified as a next-generation global innovator in molecular pathology, winning Series A seed investment of €5 million from investment partners Sioux Technologies, BOM Brabant Ventures, the Netherlands Enterprise Agency and other private investors.
Companies from across the globe provide updates to their business and pipeline.
While the conditions surrounding the City by the Bay are in a negative light, there is still a significant amount of positive news coming out of the conference.
The Institute of Cancer Research, London, strongly welcomes the recommendation by the Scottish Medicines Consortium to make the prostate cancer drug abiraterone, when given alongside hormone therapy, available to men with advanced prostate cancer as first-line treatment on the NHS in Scotland.
Oxfordshire companies which are progressing valuable innovations can apply now for The Oxford Science Park Innovation Award, one of 2020’s Oxfordshire Business Awards.
apceth Biopharma GmbH, a subsidiary of Hitachi Chemical Co., Ltd. and a leading company for the manufacturing of cell and gene therapeutics, starts the commercial manufacturing of Zynteglo™ ▼, a product of bluebird bio, Inc.
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation No 596/2014.
PRESS RELEASES